Multiple myeloma (MM) is an incurable malignancy of plasma cells marked by extreme genetic and phenotypic heterogeneity.  Chromosomal hyperdiploidy or recurrent chromosomal translocations involving the immunoglobulin heavy chain locus primarily characterize this disease, with an abundance of mutations targeting the RAS and NF-kB pathways, among others.  While the genetics of MM have been well-annotated, much less is known about pathogenic signaling in MM or how common mutations may contribute to oncogenic signaling.  My research program utilizes cutting-edge proteogenomic techniques, high-resolution microscopy imaging and biochemical approaches to discover molecular mechanisms of pathogenic signaling in MM, with the goal of finding new opportunities for the targeted treatment of MM.